#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Triple-negative breast cancer ( TNBC ) is a heterogeneous disease , characterized by aggressive clinical behavior , poor prognosis , a significantly increased risk of relapse , and shorter survival rates than patients affected by other molecular subtypes of breast cancer .
3-1	17-32	Triple-negative	abstract[3]	new[3]	appos	3-5[0_3]
3-2	33-39	breast	abstract[3]	new[3]	_	_
3-3	40-46	cancer	abstract[3]	new[3]	_	_
3-4	47-48	(	_	_	_	_
3-5	49-53	TNBC	abstract	giv	coref	3-8[5_0]
3-6	54-55	)	_	_	_	_
3-7	56-58	is	_	_	_	_
3-8	59-60	a	abstract[5]	giv[5]	coref	3-40[14_5]
3-9	61-74	heterogeneous	abstract[5]	giv[5]	_	_
3-10	75-82	disease	abstract[5]	giv[5]	_	_
3-11	83-84	,	_	_	_	_
3-12	85-98	characterized	_	_	_	_
3-13	99-101	by	_	_	_	_
3-14	102-112	aggressive	abstract[6]	new[6]	_	_
3-15	113-121	clinical	abstract[6]	new[6]	_	_
3-16	122-130	behavior	abstract[6]	new[6]	_	_
3-17	131-132	,	_	_	_	_
3-18	133-137	poor	abstract[7]	new[7]	_	_
3-19	138-147	prognosis	abstract[7]	new[7]	_	_
3-20	148-149	,	_	_	_	_
3-21	150-151	a	abstract[8]	new[8]	coref	14-15[90_8]
3-22	152-165	significantly	abstract[8]	new[8]	_	_
3-23	166-175	increased	abstract[8]	new[8]	_	_
3-24	176-180	risk	abstract[8]	new[8]	_	_
3-25	181-183	of	abstract[8]	new[8]	_	_
3-26	184-191	relapse	abstract[8]|event	new[8]|new	_	_
3-27	192-193	,	_	_	_	_
3-28	194-197	and	_	_	_	_
3-29	198-205	shorter	abstract[11]	new[11]	_	_
3-30	206-214	survival	event|abstract[11]	new|new[11]	_	_
3-31	215-220	rates	abstract[11]	new[11]	_	_
3-32	221-225	than	abstract[11]	new[11]	_	_
3-33	226-234	patients	abstract[11]|person	new[11]|new	coref	11-1[60_0]
3-34	235-243	affected	_	_	_	_
3-35	244-246	by	_	_	_	_
3-36	247-252	other	abstract[13]	new[13]	_	_
3-37	253-262	molecular	abstract[13]	new[13]	_	_
3-38	263-271	subtypes	abstract[13]	new[13]	_	_
3-39	272-274	of	abstract[13]	new[13]	_	_
3-40	275-281	breast	abstract[13]|abstract[14]	new[13]|giv[14]	coref	4-1[0_14]
3-41	282-288	cancer	abstract[13]|abstract[14]	new[13]|giv[14]	_	_
3-42	289-290	.	_	_	_	_

#Text=TNBC is clinically defined as tumors that lack expression of the estrogen receptor ( ER ) , progesterone receptor ( PR ) , and HER2 amplification .
4-1	291-295	TNBC	event	giv	coref	7-17[39_0]
4-2	296-298	is	_	_	_	_
4-3	299-309	clinically	_	_	_	_
4-4	310-317	defined	_	_	_	_
4-5	318-320	as	_	_	_	_
4-6	321-327	tumors	_	_	_	_
4-7	328-332	that	_	_	_	_
4-8	333-337	lack	_	_	_	_
4-9	338-348	expression	abstract[16]	new[16]	coref	17-7[112_16]
4-10	349-351	of	abstract[16]	new[16]	_	_
4-11	352-355	the	abstract[16]|substance[18]	new[16]|new[18]	_	_
4-12	356-364	estrogen	abstract[16]|substance|substance[18]	new[16]|new|new[18]	_	_
4-13	365-373	receptor	abstract[16]|substance[18]	new[16]|new[18]	_	_
4-14	374-375	(	_	_	_	_
4-15	376-378	ER	person	new	_	_
4-16	379-380	)	_	_	_	_
4-17	381-382	,	_	_	_	_
4-18	383-395	progesterone	object|substance[21]	new|new[21]	_	_
4-19	396-404	receptor	substance[21]	new[21]	_	_
4-20	405-406	(	_	_	_	_
4-21	407-409	PR	person	new	_	_
4-22	410-411	)	_	_	_	_
4-23	412-413	,	_	_	_	_
4-24	414-417	and	_	_	_	_
4-25	418-422	HER2	abstract|abstract[24]	new|new[24]	ana|ana	5-1[0_24]|5-1[0_24]
4-26	423-436	amplification	abstract[24]	new[24]	_	_
4-27	437-438	.	_	_	_	_

#Text=It affects primarily younger premenopausal women and tends to have higher incidences in African American women , although recent studies reported no differences in clinical outcomes between Caucasian and African American women after adjusting for socioeconomic factors .
5-1	439-441	It	abstract	giv	_	_
5-2	442-449	affects	_	_	_	_
5-3	450-459	primarily	person[27]	new[27]	coref	5-14[29_27]
5-4	460-467	younger	person[27]	new[27]	_	_
5-5	468-481	premenopausal	event|person[27]	new|new[27]	_	_
5-6	482-487	women	person[27]	new[27]	_	_
5-7	488-491	and	_	_	_	_
5-8	492-497	tends	_	_	_	_
5-9	498-500	to	_	_	_	_
5-10	501-505	have	_	_	_	_
5-11	506-512	higher	abstract[28]	new[28]	_	_
5-12	513-523	incidences	abstract[28]	new[28]	_	_
5-13	524-526	in	abstract[28]	new[28]	_	_
5-14	527-534	African	abstract[28]|person[29]	new[28]|giv[29]	_	_
5-15	535-543	American	abstract[28]|person[29]	new[28]|giv[29]	_	_
5-16	544-549	women	abstract[28]|person[29]	new[28]|giv[29]	_	_
5-17	550-551	,	_	_	_	_
5-18	552-560	although	_	_	_	_
5-19	561-567	recent	abstract[30]	new[30]	coref	15-11[95_30]
5-20	568-575	studies	abstract[30]	new[30]	_	_
5-21	576-584	reported	_	_	_	_
5-22	585-587	no	abstract[31]	new[31]	_	_
5-23	588-599	differences	abstract[31]	new[31]	_	_
5-24	600-602	in	abstract[31]	new[31]	_	_
5-25	603-611	clinical	abstract[31]|abstract[32]	new[31]|new[32]	_	_
5-26	612-620	outcomes	abstract[31]|abstract[32]	new[31]|new[32]	_	_
5-27	621-628	between	abstract[31]|abstract[32]	new[31]|new[32]	_	_
5-28	629-638	Caucasian	abstract[31]|abstract[32]|person[33]	new[31]|new[32]|new[33]	_	_
5-29	639-642	and	abstract[31]|abstract[32]|person[33]	new[31]|new[32]|new[33]	_	_
5-30	643-650	African	abstract[31]|abstract[32]|person[33]	new[31]|new[32]|new[33]	_	_
5-31	651-659	American	abstract[31]|abstract[32]|person[33]	new[31]|new[32]|new[33]	_	_
5-32	660-665	women	abstract[31]|abstract[32]|person[33]	new[31]|new[32]|new[33]	_	_
5-33	666-671	after	_	_	_	_
5-34	672-681	adjusting	_	_	_	_
5-35	682-685	for	_	_	_	_
5-36	686-699	socioeconomic	abstract[34]	new[34]	_	_
5-37	700-707	factors	abstract[34]	new[34]	_	_
5-38	708-709	.	_	_	_	_

#Text=Currently , there are no effective targeted therapies .
6-1	710-719	Currently	_	_	_	_
6-2	720-721	,	_	_	_	_
6-3	722-727	there	_	_	_	_
6-4	728-731	are	_	_	_	_
6-5	732-734	no	abstract[35]	new[35]	coref	9-12[51_35]
6-6	735-744	effective	abstract[35]	new[35]	_	_
6-7	745-753	targeted	abstract[35]	new[35]	_	_
6-8	754-763	therapies	abstract[35]	new[35]	_	_
6-9	764-765	.	_	_	_	_

#Text=Cytotoxic chemotherapy remains the only effective therapeutic modality for this aggressive and often lethal type of breast cancer .
7-1	766-775	Cytotoxic	abstract[36]	new[36]	_	_
7-2	776-788	chemotherapy	abstract[36]	new[36]	_	_
7-3	789-796	remains	_	_	_	_
7-4	797-800	the	abstract[37]	new[37]	_	_
7-5	801-805	only	abstract[37]	new[37]	_	_
7-6	806-815	effective	abstract[37]	new[37]	_	_
7-7	816-827	therapeutic	abstract[37]	new[37]	_	_
7-8	828-836	modality	abstract[37]	new[37]	_	_
7-9	837-840	for	abstract[37]	new[37]	_	_
7-10	841-845	this	abstract[37]|abstract[38]	new[37]|new[38]	_	_
7-11	846-856	aggressive	abstract[37]|abstract[38]	new[37]|new[38]	_	_
7-12	857-860	and	abstract[37]|abstract[38]	new[37]|new[38]	_	_
7-13	861-866	often	abstract[37]|abstract[38]	new[37]|new[38]	_	_
7-14	867-873	lethal	abstract[37]|abstract[38]	new[37]|new[38]	_	_
7-15	874-878	type	abstract[37]|abstract[38]	new[37]|new[38]	_	_
7-16	879-881	of	abstract[37]|abstract[38]	new[37]|new[38]	_	_
7-17	882-888	breast	abstract[37]|abstract[38]|abstract[39]	new[37]|new[38]|giv[39]	coref	9-8[0_39]
7-18	889-895	cancer	abstract[37]|abstract[38]|abstract[39]	new[37]|new[38]|giv[39]	_	_
7-19	896-897	.	_	_	_	_

#Text=Therefore , there is an urgent need for the discovery of molecular markers and targets for the development of novel targeted therapeutics .
8-1	898-907	Therefore	_	_	_	_
8-2	908-909	,	_	_	_	_
8-3	910-915	there	_	_	_	_
8-4	916-918	is	_	_	_	_
8-5	919-921	an	abstract[40]	new[40]	coref	18-9[118_40]
8-6	922-928	urgent	abstract[40]	new[40]	_	_
8-7	929-933	need	abstract[40]	new[40]	_	_
8-8	934-937	for	abstract[40]	new[40]	_	_
8-9	938-941	the	abstract[40]|abstract[41]	new[40]|new[41]	_	_
8-10	942-951	discovery	abstract[40]|abstract[41]	new[40]|new[41]	_	_
8-11	952-954	of	abstract[40]|abstract[41]	new[40]|new[41]	_	_
8-12	955-964	molecular	abstract[40]|abstract[41]|abstract[42]	new[40]|new[41]|new[42]	coref	21-12[140_42]
8-13	965-972	markers	abstract[40]|abstract[41]|abstract[42]	new[40]|new[41]|new[42]	_	_
8-14	973-976	and	abstract[40]|abstract[41]	new[40]|new[41]	_	_
8-15	977-984	targets	abstract[40]|abstract[41]|abstract	new[40]|new[41]|new	_	_
8-16	985-988	for	_	_	_	_
8-17	989-992	the	abstract[44]	new[44]	_	_
8-18	993-1004	development	abstract[44]	new[44]	_	_
8-19	1005-1007	of	abstract[44]	new[44]	_	_
8-20	1008-1013	novel	abstract[44]	new[44]	_	_
8-21	1014-1022	targeted	_	_	_	_
8-22	1023-1035	therapeutics	abstract	new	_	_
8-23	1036-1037	.	_	_	_	_

#Text=Our understanding of the molecular basis of TNBC and development of effective targeted therapies has been hampered by the complexity and multifactorial etiology of the disease .
9-1	1038-1041	Our	person|abstract[47]	acc|new[47]	ana|ana	25-1|25-1
9-2	1042-1055	understanding	abstract[47]	new[47]	_	_
9-3	1056-1058	of	abstract[47]	new[47]	_	_
9-4	1059-1062	the	abstract[47]|abstract[48]	new[47]|new[48]	_	_
9-5	1063-1072	molecular	abstract[47]|abstract[48]	new[47]|new[48]	_	_
9-6	1073-1078	basis	abstract[47]|abstract[48]	new[47]|new[48]	_	_
9-7	1079-1081	of	abstract[47]|abstract[48]	new[47]|new[48]	_	_
9-8	1082-1086	TNBC	abstract[47]|abstract[48]|abstract	new[47]|new[48]|giv	coref	9-25[54_0]
9-9	1087-1090	and	abstract[47]	new[47]	_	_
9-10	1091-1102	development	abstract[47]|abstract[50]	new[47]|new[50]	_	_
9-11	1103-1105	of	abstract[47]|abstract[50]	new[47]|new[50]	_	_
9-12	1106-1115	effective	abstract[47]|abstract[50]|abstract[51]	new[47]|new[50]|giv[51]	_	_
9-13	1116-1124	targeted	abstract[47]|abstract[50]|abstract[51]	new[47]|new[50]|giv[51]	_	_
9-14	1125-1134	therapies	abstract[47]|abstract[50]|abstract[51]	new[47]|new[50]|giv[51]	_	_
9-15	1135-1138	has	_	_	_	_
9-16	1139-1143	been	_	_	_	_
9-17	1144-1152	hampered	_	_	_	_
9-18	1153-1155	by	_	_	_	_
9-19	1156-1159	the	abstract[52]	new[52]	_	_
9-20	1160-1170	complexity	abstract[52]	new[52]	_	_
9-21	1171-1174	and	_	_	_	_
9-22	1175-1189	multifactorial	abstract[53]	new[53]	_	_
9-23	1190-1198	etiology	abstract[53]	new[53]	_	_
9-24	1199-1201	of	abstract[53]	new[53]	_	_
9-25	1202-1205	the	abstract[53]|abstract[54]	new[53]|giv[54]	coref	10-10[0_54]
9-26	1206-1213	disease	abstract[53]|abstract[54]	new[53]|giv[54]	_	_
9-27	1214-1215	.	_	_	_	_

#Text=Genes play a major role in the pathogenesis of TNBC .
10-1	1216-1221	Genes	abstract	new	coref	11-9[64_0]
10-2	1222-1226	play	_	_	_	_
10-3	1227-1228	a	abstract[56]	new[56]	coref	15-7[93_56]
10-4	1229-1234	major	abstract[56]	new[56]	_	_
10-5	1235-1239	role	abstract[56]	new[56]	_	_
10-6	1240-1242	in	abstract[56]	new[56]	_	_
10-7	1243-1246	the	abstract[56]|abstract[57]	new[56]|new[57]	coref	27-26[200_57]
10-8	1247-1259	pathogenesis	abstract[56]|abstract[57]	new[56]|new[57]	_	_
10-9	1260-1262	of	abstract[56]|abstract[57]	new[56]|new[57]	_	_
10-10	1263-1267	TNBC	abstract[56]|abstract[57]|abstract	new[56]|new[57]|giv	coref	11-4
10-11	1268-1269	.	_	_	_	_

#Text=The majority of TNBC patients carry mutations in the highly penetrant cancer susceptibility genes BRCA1 and BRCA2 .
11-1	1270-1273	The	person[60]	giv[60]	_	_
11-2	1274-1282	majority	person[60]	giv[60]	_	_
11-3	1283-1285	of	person[60]	giv[60]	_	_
11-4	1286-1290	TNBC	event|person[60]	giv|giv[60]	coref	11-12
11-5	1291-1299	patients	person[60]	giv[60]	_	_
11-6	1300-1305	carry	_	_	_	_
11-7	1306-1315	mutations	abstract	new	coref	12-13[75_0]
11-8	1316-1318	in	_	_	_	_
11-9	1319-1322	the	abstract[63]|abstract[64]	new[63]|giv[64]	coref|coref	13-13[84_64]|13-13[84_64]
11-10	1323-1329	highly	abstract[63]|abstract[64]	new[63]|giv[64]	_	_
11-11	1330-1339	penetrant	abstract[63]|abstract[64]	new[63]|giv[64]	_	_
11-12	1340-1346	cancer	abstract|abstract[63]|abstract[64]	giv|new[63]|giv[64]	coref	12-3
11-13	1347-1361	susceptibility	abstract[63]|abstract[64]	new[63]|giv[64]	_	_
11-14	1362-1367	genes	abstract[64]	giv[64]	_	_
11-15	1368-1373	BRCA1	abstract[64]|abstract|abstract[66]	giv[64]|new|new[66]	coref|coref|coref|coref	12-9[72_0]|12-9[73_66]|12-9[72_0]|12-9[73_66]
11-16	1374-1377	and	abstract[64]|abstract[66]	giv[64]|new[66]	_	_
11-17	1378-1383	BRCA2	abstract[64]|abstract[66]|abstract	giv[64]|new[66]|new	coref	12-13
11-18	1384-1385	.	_	_	_	_

#Text=In unselected TNBC cases , the prevalence of pathogenic germline BRCA1 and BRCA2 mutations is approximately twice as high as in breast cancer overall .
12-1	1386-1388	In	_	_	_	_
12-2	1389-1399	unselected	abstract[69]	new[69]	_	_
12-3	1400-1404	TNBC	abstract|abstract[69]	giv|new[69]	coref	12-23
12-4	1405-1410	cases	abstract[69]	new[69]	_	_
12-5	1411-1412	,	_	_	_	_
12-6	1413-1416	the	abstract[70]	new[70]	_	_
12-7	1417-1427	prevalence	abstract[70]	new[70]	_	_
12-8	1428-1430	of	abstract[70]	new[70]	_	_
12-9	1431-1441	pathogenic	abstract[70]|abstract[72]|abstract[73]	new[70]|giv[72]|giv[73]	coref|coref|coref|coref	13-3[0_72]|13-3[79_73]|13-3[0_72]|13-3[79_73]
12-10	1442-1450	germline	abstract[70]|abstract|abstract[72]|abstract[73]	new[70]|new|giv[72]|giv[73]	_	_
12-11	1451-1456	BRCA1	abstract[70]|abstract[72]|abstract[73]	new[70]|giv[72]|giv[73]	_	_
12-12	1457-1460	and	abstract[70]|abstract[73]	new[70]|giv[73]	_	_
12-13	1461-1466	BRCA2	abstract[70]|abstract[73]|abstract|abstract[75]	new[70]|giv[73]|giv|giv[75]	coref|coref|coref|coref	13-5|23-40[170_75]|13-5|23-40[170_75]
12-14	1467-1476	mutations	abstract[70]|abstract[73]|abstract[75]	new[70]|giv[73]|giv[75]	_	_
12-15	1477-1479	is	_	_	_	_
12-16	1480-1493	approximately	_	_	_	_
12-17	1494-1499	twice	_	_	_	_
12-18	1500-1502	as	_	_	_	_
12-19	1503-1507	high	_	_	_	_
12-20	1508-1510	as	_	_	_	_
12-21	1511-1513	in	_	_	_	_
12-22	1514-1520	breast	place	new	coref	13-10
12-23	1521-1527	cancer	abstract	giv	coref	13-11
12-24	1528-1535	overall	_	_	_	_
12-25	1536-1537	.	_	_	_	_

#Text=Apart from BRCA1 and BRCA2 , the rarely mutated breast cancer predisposition genes PALB2 and FANCM have been associated with TNBC .
13-1	1538-1543	Apart	abstract[83]	new[83]	_	_
13-2	1544-1548	from	abstract[83]	new[83]	_	_
13-3	1549-1554	BRCA1	abstract|abstract[79]|abstract[83]	giv|giv[79]|new[83]	_	_
13-4	1555-1558	and	abstract[79]|abstract[83]	giv[79]|new[83]	_	_
13-5	1559-1564	BRCA2	abstract[79]|abstract|abstract[83]	giv[79]|giv|new[83]	_	_
13-6	1565-1566	,	abstract[83]	new[83]	_	_
13-7	1567-1570	the	abstract[83]	new[83]	_	_
13-8	1571-1577	rarely	abstract[83]	new[83]	_	_
13-9	1578-1585	mutated	abstract[83]	new[83]	_	_
13-10	1586-1592	breast	place|abstract[83]	giv|new[83]	_	_
13-11	1593-1599	cancer	abstract|abstract[83]	giv|new[83]	coref	13-21
13-12	1600-1614	predisposition	abstract[83]	new[83]	_	_
13-13	1615-1620	genes	abstract[84]	giv[84]	coref	14-7[88_84]
13-14	1621-1626	PALB2	abstract[84]	giv[84]	_	_
13-15	1627-1630	and	abstract[84]	giv[84]	_	_
13-16	1631-1636	FANCM	abstract[84]	giv[84]	_	_
13-17	1637-1641	have	_	_	_	_
13-18	1642-1646	been	_	_	_	_
13-19	1647-1657	associated	_	_	_	_
13-20	1658-1662	with	_	_	_	_
13-21	1663-1667	TNBC	abstract	giv	coref	14-20
13-22	1668-1669	.	_	_	_	_

#Text=Multigene panel testing has also identified genes with high and moderate penetrance associated with an increased risk of developing TNBC .
14-1	1670-1679	Multigene	abstract[87]	new[87]	_	_
14-2	1680-1685	panel	person|abstract[87]	new|new[87]	_	_
14-3	1686-1693	testing	abstract[87]	new[87]	_	_
14-4	1694-1697	has	_	_	_	_
14-5	1698-1702	also	_	_	_	_
14-6	1703-1713	identified	_	_	_	_
14-7	1714-1719	genes	abstract[88]	giv[88]	coref	15-4[0_88]
14-8	1720-1724	with	abstract[88]	giv[88]	_	_
14-9	1725-1729	high	abstract[88]|abstract[89]	giv[88]|new[89]	_	_
14-10	1730-1733	and	abstract[88]|abstract[89]	giv[88]|new[89]	_	_
14-11	1734-1742	moderate	abstract[88]|abstract[89]	giv[88]|new[89]	_	_
14-12	1743-1753	penetrance	abstract[88]|abstract[89]	giv[88]|new[89]	_	_
14-13	1754-1764	associated	_	_	_	_
14-14	1765-1769	with	_	_	_	_
14-15	1770-1772	an	abstract[90]	giv[90]	coref	15-16[97_90]
14-16	1773-1782	increased	abstract[90]	giv[90]	_	_
14-17	1783-1787	risk	abstract[90]	giv[90]	_	_
14-18	1788-1790	of	_	_	_	_
14-19	1791-1801	developing	_	_	_	_
14-20	1802-1806	TNBC	abstract	giv	coref	15-16
14-21	1807-1808	.	_	_	_	_

#Text=However , although genes may play a strong role , molecular epidemiology studies suggest that TNBC risk is largely determined by interactions between genes and environment .
15-1	1809-1816	However	_	_	_	_
15-2	1817-1818	,	_	_	_	_
15-3	1819-1827	although	_	_	_	_
15-4	1828-1833	genes	abstract	giv	coref	15-24[99_0]
15-5	1834-1837	may	_	_	_	_
15-6	1838-1842	play	_	_	_	_
15-7	1843-1844	a	abstract[93]	giv[93]	_	_
15-8	1845-1851	strong	abstract[93]	giv[93]	_	_
15-9	1852-1856	role	abstract[93]	giv[93]	_	_
15-10	1857-1858	,	_	_	_	_
15-11	1859-1868	molecular	abstract[95]	giv[95]	coref	22-4[148_95]
15-12	1869-1881	epidemiology	abstract|abstract[95]	new|giv[95]	_	_
15-13	1882-1889	studies	abstract[95]	giv[95]	_	_
15-14	1890-1897	suggest	_	_	_	_
15-15	1898-1902	that	_	_	_	_
15-16	1903-1907	TNBC	abstract|abstract[97]	giv|giv[97]	coref|coref|coref|coref	16-13|22-18[152_97]|16-13|22-18[152_97]
15-17	1908-1912	risk	abstract[97]	giv[97]	_	_
15-18	1913-1915	is	_	_	_	_
15-19	1916-1923	largely	_	_	_	_
15-20	1924-1934	determined	_	_	_	_
15-21	1935-1937	by	_	_	_	_
15-22	1938-1950	interactions	abstract[98]	new[98]	coref	25-4[175_98]
15-23	1951-1958	between	abstract[98]	new[98]	_	_
15-24	1959-1964	genes	abstract[98]|abstract[99]	new[98]|giv[99]	coref	17-10[113_99]
15-25	1965-1968	and	abstract[98]|abstract[99]	new[98]|giv[99]	_	_
15-26	1969-1980	environment	abstract[98]|abstract[99]|abstract	new[98]|giv[99]|new	_	_
15-27	1981-1982	.	_	_	_	_

#Text=Increased attention has focused on epigenetic variation such as DNA methylation and TNBC because enduring epigenetic landmarks define the tumor microenvironment .
16-1	1983-1992	Increased	abstract[101]	new[101]	_	_
16-2	1993-2002	attention	abstract[101]	new[101]	_	_
16-3	2003-2006	has	_	_	_	_
16-4	2007-2014	focused	_	_	_	_
16-5	2015-2017	on	_	_	_	_
16-6	2018-2028	epigenetic	abstract[102]	new[102]	coref	18-26[0_102]
16-7	2029-2038	variation	abstract[102]	new[102]	_	_
16-8	2039-2043	such	abstract[102]	new[102]	_	_
16-9	2044-2046	as	abstract[102]	new[102]	_	_
16-10	2047-2050	DNA	abstract[102]|abstract|abstract[104]	new[102]|new|new[104]	coref|coref|coref|coref	17-4|17-4[110_104]|17-4|17-4[110_104]
16-11	2051-2062	methylation	abstract[102]|abstract[104]	new[102]|new[104]	_	_
16-12	2063-2066	and	abstract[102]	new[102]	_	_
16-13	2067-2071	TNBC	abstract[102]|abstract	new[102]|giv	coref	18-31
16-14	2072-2079	because	_	_	_	_
16-15	2080-2088	enduring	_	_	_	_
16-16	2089-2099	epigenetic	abstract[106]	new[106]	_	_
16-17	2100-2109	landmarks	abstract[106]	new[106]	_	_
16-18	2110-2116	define	_	_	_	_
16-19	2117-2120	the	abstract[108]	new[108]	_	_
16-20	2121-2126	tumor	abstract|abstract[108]	new|new[108]	coref	23-9
16-21	2127-2143	microenvironment	abstract[108]	new[108]	_	_
16-22	2144-2145	.	_	_	_	_

#Text=Moreover , because DNA methylation regulates gene expression , aberrant methylated genes could serve as complementary diagnostic tools , prognostic markers and predictors of response to treatment .
17-1	2146-2154	Moreover	_	_	_	_
17-2	2155-2156	,	_	_	_	_
17-3	2157-2164	because	_	_	_	_
17-4	2165-2168	DNA	substance|abstract[110]	giv|giv[110]	coref|coref|coref|coref	26-22|26-23[0_110]|26-22|26-23[0_110]
17-5	2169-2180	methylation	abstract[110]	giv[110]	_	_
17-6	2181-2190	regulates	_	_	_	_
17-7	2191-2195	gene	abstract|abstract[112]	new|giv[112]	coref|coref|coref|coref	21-25|21-25[144_112]|21-25|21-25[144_112]
17-8	2196-2206	expression	abstract[112]	giv[112]	_	_
17-9	2207-2208	,	_	_	_	_
17-10	2209-2217	aberrant	abstract[113]	giv[113]	coref	25-7[0_113]
17-11	2218-2228	methylated	abstract[113]	giv[113]	_	_
17-12	2229-2234	genes	abstract[113]	giv[113]	_	_
17-13	2235-2240	could	_	_	_	_
17-14	2241-2246	serve	_	_	_	_
17-15	2247-2249	as	_	_	_	_
17-16	2250-2263	complementary	_	_	_	_
17-17	2264-2274	diagnostic	_	_	_	_
17-18	2275-2280	tools	_	_	_	_
17-19	2281-2282	,	_	_	_	_
17-20	2283-2293	prognostic	_	_	_	_
17-21	2294-2301	markers	_	_	_	_
17-22	2302-2305	and	_	_	_	_
17-23	2306-2316	predictors	_	_	_	_
17-24	2317-2319	of	_	_	_	_
17-25	2320-2328	response	event[114]	new[114]	_	_
17-26	2329-2331	to	event[114]	new[114]	_	_
17-27	2332-2341	treatment	event[114]|event	new[114]|new	_	_
17-28	2342-2343	.	_	_	_	_

#Text=Thus , a critical knowledge gap , and an unmet medical need , is understanding the interplay between genetic ( both germline and somatic ) variation and epigenomic variation in TNBC .
18-1	2344-2348	Thus	_	_	_	_
18-2	2349-2350	,	_	_	_	_
18-3	2351-2352	a	abstract[117]	new[117]	_	_
18-4	2353-2361	critical	abstract[117]	new[117]	_	_
18-5	2362-2371	knowledge	abstract|abstract[117]	new|new[117]	_	_
18-6	2372-2375	gap	abstract[117]	new[117]	_	_
18-7	2376-2377	,	_	_	_	_
18-8	2378-2381	and	_	_	_	_
18-9	2382-2384	an	abstract[118]	giv[118]	_	_
18-10	2385-2390	unmet	abstract[118]	giv[118]	_	_
18-11	2391-2398	medical	abstract[118]	giv[118]	_	_
18-12	2399-2403	need	abstract[118]	giv[118]	_	_
18-13	2404-2405	,	_	_	_	_
18-14	2406-2408	is	_	_	_	_
18-15	2409-2422	understanding	_	_	_	_
18-16	2423-2426	the	abstract[119]	new[119]	coref	26-27[191_119]
18-17	2427-2436	interplay	abstract[119]	new[119]	_	_
18-18	2437-2444	between	abstract[119]	new[119]	_	_
18-19	2445-2452	genetic	abstract[119]|abstract	new[119]|new	appos	18-21[121_0]
18-20	2453-2454	(	_	_	_	_
18-21	2455-2459	both	abstract[121]	giv[121]	coref	25-9[0_121]
18-22	2460-2468	germline	abstract[121]	giv[121]	_	_
18-23	2469-2472	and	_	_	_	_
18-24	2473-2480	somatic	_	_	_	_
18-25	2481-2482	)	_	_	_	_
18-26	2483-2492	variation	abstract	giv	coref	18-28[123_0]
18-27	2493-2496	and	_	_	_	_
18-28	2497-2507	epigenomic	abstract[123]	giv[123]	coref	26-10[187_123]
18-29	2508-2517	variation	abstract[123]	giv[123]	_	_
18-30	2518-2520	in	abstract[123]	giv[123]	_	_
18-31	2521-2525	TNBC	abstract[123]|abstract	giv[123]|giv	coref	19-12
18-32	2526-2527	.	_	_	_	_

#Text=Advances in microarray technology have enabled molecular classification of subtypes of TNBC .
19-1	2528-2536	Advances	abstract[125]	new[125]	_	_
19-2	2537-2539	in	abstract[125]	new[125]	_	_
19-3	2540-2550	microarray	abstract[125]|object|abstract[127]	new[125]|new|new[127]	_	_
19-4	2551-2561	technology	abstract[125]|abstract[127]	new[125]|new[127]	_	_
19-5	2562-2566	have	_	_	_	_
19-6	2567-2574	enabled	_	_	_	_
19-7	2575-2584	molecular	abstract[128]	new[128]	_	_
19-8	2585-2599	classification	abstract[128]	new[128]	_	_
19-9	2600-2602	of	abstract[128]	new[128]	_	_
19-10	2603-2611	subtypes	abstract[128]|abstract[129]	new[128]|new[129]	_	_
19-11	2612-2614	of	abstract[128]|abstract[129]	new[128]|new[129]	_	_
19-12	2615-2619	TNBC	abstract[128]|abstract[129]|abstract	new[128]|new[129]|giv	coref	21-28[145_0]
19-13	2620-2621	.	_	_	_	_

#Text=At least , several clinically validated prognostic assays including the Prosigna PAM50 , MammaPrint and Oncotype DX , have been developed using transcription profiling .
20-1	2622-2624	At	abstract[131]	new[131]	_	_
20-2	2625-2630	least	abstract[131]	new[131]	_	_
20-3	2631-2632	,	abstract[131]	new[131]	_	_
20-4	2633-2640	several	abstract[131]	new[131]	_	_
20-5	2641-2651	clinically	abstract[131]	new[131]	_	_
20-6	2652-2661	validated	abstract[131]	new[131]	_	_
20-7	2662-2672	prognostic	abstract[131]	new[131]	_	_
20-8	2673-2679	assays	abstract[131]	new[131]	_	_
20-9	2680-2689	including	abstract[131]	new[131]	_	_
20-10	2690-2693	the	abstract[131]|abstract[133]	new[131]|new[133]	_	_
20-11	2694-2702	Prosigna	abstract[131]|place|abstract[133]	new[131]|new|new[133]	_	_
20-12	2703-2708	PAM50	abstract[131]|abstract[133]	new[131]|new[133]	_	_
20-13	2709-2710	,	abstract[131]	new[131]	_	_
20-14	2711-2721	MammaPrint	abstract[131]|object	new[131]|new	_	_
20-15	2722-2725	and	abstract[131]	new[131]	_	_
20-16	2726-2734	Oncotype	abstract[131]|abstract|abstract[136]	new[131]|new|new[136]	_	_
20-17	2735-2737	DX	abstract[131]|abstract[136]	new[131]|new[136]	_	_
20-18	2738-2739	,	_	_	_	_
20-19	2740-2744	have	_	_	_	_
20-20	2745-2749	been	_	_	_	_
20-21	2750-2759	developed	_	_	_	_
20-22	2760-2765	using	_	_	_	_
20-23	2766-2779	transcription	abstract|abstract[138]	new|new[138]	_	_
20-24	2780-2789	profiling	abstract[138]	new[138]	_	_
20-25	2790-2791	.	_	_	_	_

#Text=However , although these primary analyses have been successful in identifying prognostic markers , they have been unsuccessful in establishing the causal association between gene expression and the disease .
21-1	2792-2799	However	_	_	_	_
21-2	2800-2801	,	_	_	_	_
21-3	2802-2810	although	_	_	_	_
21-4	2811-2816	these	abstract[139]	new[139]	_	_
21-5	2817-2824	primary	abstract[139]	new[139]	_	_
21-6	2825-2833	analyses	abstract[139]	new[139]	_	_
21-7	2834-2838	have	_	_	_	_
21-8	2839-2843	been	_	_	_	_
21-9	2844-2854	successful	_	_	_	_
21-10	2855-2857	in	_	_	_	_
21-11	2858-2869	identifying	_	_	_	_
21-12	2870-2880	prognostic	abstract[140]	giv[140]	ana	21-15[0_140]
21-13	2881-2888	markers	abstract[140]	giv[140]	_	_
21-14	2889-2890	,	_	_	_	_
21-15	2891-2895	they	abstract	giv	_	_
21-16	2896-2900	have	_	_	_	_
21-17	2901-2905	been	_	_	_	_
21-18	2906-2918	unsuccessful	_	_	_	_
21-19	2919-2921	in	_	_	_	_
21-20	2922-2934	establishing	_	_	_	_
21-21	2935-2938	the	abstract[142]	new[142]	coref	22-5[0_142]
21-22	2939-2945	causal	abstract[142]	new[142]	_	_
21-23	2946-2957	association	abstract[142]	new[142]	_	_
21-24	2958-2965	between	abstract[142]	new[142]	_	_
21-25	2966-2970	gene	abstract[142]|abstract|abstract[144]	new[142]|giv|giv[144]	coref|coref|coref|coref	26-12|26-13[0_144]|26-12|26-13[0_144]
21-26	2971-2981	expression	abstract[142]|abstract[144]	new[142]|giv[144]	_	_
21-27	2982-2985	and	abstract[142]	new[142]	_	_
21-28	2986-2989	the	abstract[142]|abstract[145]	new[142]|giv[145]	coref	22-23[0_145]
21-29	2990-2997	disease	abstract[142]|abstract[145]	new[142]|giv[145]	_	_
21-30	2998-2999	.	_	_	_	_

#Text=High-throughput genotyping using genome-wide association studies ( GWAS ) has enabled discovery of genetic variants associated with an increased risk of developing TNBC .
22-1	3000-3015	High-throughput	abstract[146]	new[146]	_	_
22-2	3016-3026	genotyping	abstract[146]	new[146]	_	_
22-3	3027-3032	using	_	_	_	_
22-4	3033-3044	genome-wide	abstract[148]	giv[148]	appos	22-8[0_148]
22-5	3045-3056	association	abstract|abstract[148]	giv|giv[148]	_	_
22-6	3057-3064	studies	abstract[148]	giv[148]	_	_
22-7	3065-3066	(	_	_	_	_
22-8	3067-3071	GWAS	abstract	giv	coref	31-12
22-9	3072-3073	)	_	_	_	_
22-10	3074-3077	has	_	_	_	_
22-11	3078-3085	enabled	_	_	_	_
22-12	3086-3095	discovery	abstract[150]	new[150]	_	_
22-13	3096-3098	of	abstract[150]	new[150]	_	_
22-14	3099-3106	genetic	abstract[150]|abstract[151]	new[150]|new[151]	_	_
22-15	3107-3115	variants	abstract[150]|abstract[151]	new[150]|new[151]	_	_
22-16	3116-3126	associated	_	_	_	_
22-17	3127-3131	with	_	_	_	_
22-18	3132-3134	an	abstract[152]	giv[152]	_	_
22-19	3135-3144	increased	abstract[152]	giv[152]	_	_
22-20	3145-3149	risk	abstract[152]	giv[152]	_	_
22-21	3150-3152	of	_	_	_	_
22-22	3153-3163	developing	_	_	_	_
22-23	3164-3168	TNBC	abstract	giv	coref	23-19
22-24	3169-3170	.	_	_	_	_

#Text=The recent surge of next generation sequencing of tumor genomes by large multicenter projects , such as The Cancer Genome Atlas ( TCGA ) and the International Cancer Genome Consortium ( ICGC ) , have generated comprehensive catalogues of somatic mutations associated with TNBC .
23-1	3171-3174	The	abstract[154]	new[154]	_	_
23-2	3175-3181	recent	abstract[154]	new[154]	_	_
23-3	3182-3187	surge	abstract[154]	new[154]	_	_
23-4	3188-3190	of	abstract[154]	new[154]	_	_
23-5	3191-3195	next	abstract[154]|abstract[156]	new[154]|new[156]	_	_
23-6	3196-3206	generation	abstract[154]|abstract|abstract[156]	new[154]|new|new[156]	_	_
23-7	3207-3217	sequencing	abstract[154]|abstract[156]	new[154]|new[156]	_	_
23-8	3218-3220	of	abstract[154]|abstract[156]	new[154]|new[156]	_	_
23-9	3221-3226	tumor	abstract[154]|abstract[156]|abstract|abstract[158]	new[154]|new[156]|giv|new[158]	_	_
23-10	3227-3234	genomes	abstract[154]|abstract[156]|abstract[158]	new[154]|new[156]|new[158]	_	_
23-11	3235-3237	by	abstract[154]|abstract[156]|abstract[158]	new[154]|new[156]|new[158]	_	_
23-12	3238-3243	large	abstract[154]|abstract[156]|abstract[158]|abstract[160]	new[154]|new[156]|new[158]|new[160]	_	_
23-13	3244-3255	multicenter	abstract[154]|abstract[156]|abstract[158]|person|abstract[160]	new[154]|new[156]|new[158]|new|new[160]	_	_
23-14	3256-3264	projects	abstract[154]|abstract[156]|abstract[158]|abstract[160]	new[154]|new[156]|new[158]|new[160]	_	_
23-15	3265-3266	,	abstract[154]|abstract[156]	new[154]|new[156]	_	_
23-16	3267-3271	such	abstract[154]|abstract[156]	new[154]|new[156]	_	_
23-17	3272-3274	as	abstract[154]|abstract[156]	new[154]|new[156]	_	_
23-18	3275-3278	The	abstract[154]|abstract[156]|person[163]	new[154]|new[156]|new[163]	_	_
23-19	3279-3285	Cancer	abstract[154]|abstract[156]|abstract|person[163]	new[154]|new[156]|giv|new[163]	coref	23-27[165_0]
23-20	3286-3292	Genome	abstract[154]|abstract[156]|abstract|person[163]	new[154]|new[156]|new|new[163]	coref	23-29
23-21	3293-3298	Atlas	abstract[154]|abstract[156]|person[163]	new[154]|new[156]|new[163]	_	_
23-22	3299-3300	(	_	_	_	_
23-23	3301-3305	TCGA	place	new	coref	31-21
23-24	3306-3307	)	_	_	_	_
23-25	3308-3311	and	_	_	_	_
23-26	3312-3315	the	organization[167]	new[167]	_	_
23-27	3316-3329	International	abstract[165]|organization[167]	giv[165]|new[167]	coref	23-44[0_165]
23-28	3330-3336	Cancer	abstract[165]|organization[167]	giv[165]|new[167]	_	_
23-29	3337-3343	Genome	abstract|organization[167]	giv|new[167]	_	_
23-30	3344-3354	Consortium	organization[167]	new[167]	_	_
23-31	3355-3356	(	_	_	_	_
23-32	3357-3361	ICGC	place	new	_	_
23-33	3362-3363	)	_	_	_	_
23-34	3364-3365	,	_	_	_	_
23-35	3366-3370	have	_	_	_	_
23-36	3371-3380	generated	_	_	_	_
23-37	3381-3394	comprehensive	abstract[169]	new[169]	_	_
23-38	3395-3405	catalogues	abstract[169]	new[169]	_	_
23-39	3406-3408	of	abstract[169]	new[169]	_	_
23-40	3409-3416	somatic	abstract[169]|abstract[170]	new[169]|giv[170]	coref	25-11[179_170]
23-41	3417-3426	mutations	abstract[169]|abstract[170]	new[169]|giv[170]	_	_
23-42	3427-3437	associated	_	_	_	_
23-43	3438-3442	with	_	_	_	_
23-44	3443-3447	TNBC	abstract	giv	coref	25-14
23-45	3448-3449	.	_	_	_	_

#Text=The clonal and mutational spectrum of primary TNBCs have also been characterized .
24-1	3450-3453	The	abstract[172]	new[172]	_	_
24-2	3454-3460	clonal	abstract[172]	new[172]	_	_
24-3	3461-3464	and	abstract[172]	new[172]	_	_
24-4	3465-3475	mutational	abstract[172]	new[172]	_	_
24-5	3476-3484	spectrum	abstract[172]	new[172]	_	_
24-6	3485-3487	of	abstract[172]	new[172]	_	_
24-7	3488-3495	primary	abstract[172]|abstract[173]	new[172]|new[173]	_	_
24-8	3496-3501	TNBCs	abstract[172]|abstract[173]	new[172]|new[173]	_	_
24-9	3502-3506	have	_	_	_	_
24-10	3507-3511	also	_	_	_	_
24-11	3512-3516	been	_	_	_	_
24-12	3517-3530	characterized	_	_	_	_
24-13	3531-3532	.	_	_	_	_

#Text=We recently reported oncogenic interactions between genes containing germline and somatic mutations in TNBC .
25-1	3533-3535	We	person	giv	ana	29-1
25-2	3536-3544	recently	_	_	_	_
25-3	3545-3553	reported	_	_	_	_
25-4	3554-3563	oncogenic	abstract[175]	giv[175]	coref	28-29[208_175]
25-5	3564-3576	interactions	abstract[175]	giv[175]	_	_
25-6	3577-3584	between	abstract[175]	giv[175]	_	_
25-7	3585-3590	genes	abstract[175]|abstract	giv[175]|giv	_	_
25-8	3591-3601	containing	_	_	_	_
25-9	3602-3610	germline	abstract|abstract[178]	giv|new[178]	coref|coref|coref|coref	26-8|26-8[184_178]|26-8|26-8[184_178]
25-10	3611-3614	and	abstract[178]	new[178]	_	_
25-11	3615-3622	somatic	abstract[178]|abstract[179]	new[178]|giv[179]	_	_
25-12	3623-3632	mutations	abstract[178]|abstract[179]	new[178]|giv[179]	_	_
25-13	3633-3635	in	abstract[178]|abstract[179]	new[178]|giv[179]	_	_
25-14	3636-3640	TNBC	abstract[178]|abstract[179]|abstract	new[178]|giv[179]|giv	coref	26-35
25-15	3641-3642	.	_	_	_	_

#Text=However , to date , information on germline , somatic and gene expression variation has not been leveraged and integrated with DNA methylation data to map the interplay between genetic and epigenetic variation in TNBC .
26-1	3643-3650	However	_	_	_	_
26-2	3651-3652	,	_	_	_	_
26-3	3653-3655	to	_	_	_	_
26-4	3656-3660	date	time	new	_	_
26-5	3661-3662	,	_	_	_	_
26-6	3663-3674	information	abstract[182]	new[182]	coref	31-7[227_182]
26-7	3675-3677	on	abstract[182]	new[182]	_	_
26-8	3678-3686	germline	abstract[182]|abstract|abstract[184]	new[182]|giv|giv[184]	coref|coref	26-30|26-30
26-9	3687-3688	,	abstract[182]|abstract[184]	new[182]|giv[184]	_	_
26-10	3689-3696	somatic	abstract[182]|abstract[184]|abstract[187]	new[182]|giv[184]|giv[187]	coref	26-30[194_187]
26-11	3697-3700	and	abstract[182]|abstract[184]|abstract[187]	new[182]|giv[184]|giv[187]	_	_
26-12	3701-3705	gene	abstract[182]|abstract[184]|abstract|abstract[187]	new[182]|giv[184]|giv|giv[187]	coref	31-23
26-13	3706-3716	expression	abstract|abstract[187]	giv|giv[187]	coref	31-23[235_0]
26-14	3717-3726	variation	abstract[187]	giv[187]	_	_
26-15	3727-3730	has	_	_	_	_
26-16	3731-3734	not	_	_	_	_
26-17	3735-3739	been	_	_	_	_
26-18	3740-3749	leveraged	_	_	_	_
26-19	3750-3753	and	_	_	_	_
26-20	3754-3764	integrated	_	_	_	_
26-21	3765-3769	with	_	_	_	_
26-22	3770-3773	DNA	substance|abstract[190]	giv|new[190]	_	_
26-23	3774-3785	methylation	abstract|abstract[190]	giv|new[190]	_	_
26-24	3786-3790	data	abstract[190]	new[190]	_	_
26-25	3791-3793	to	_	_	_	_
26-26	3794-3797	map	_	_	_	_
26-27	3798-3801	the	abstract[191]	giv[191]	coref	29-9[213_191]
26-28	3802-3811	interplay	abstract[191]	giv[191]	_	_
26-29	3812-3819	between	abstract[191]	giv[191]	_	_
26-30	3820-3827	genetic	abstract[191]|abstract|abstract[194]	giv[191]|giv|giv[194]	coref|coref	29-20[0_194]|29-20[0_194]
26-31	3828-3831	and	abstract[191]|abstract[194]	giv[191]|giv[194]	_	_
26-32	3832-3842	epigenetic	abstract[191]|abstract|abstract[194]	giv[191]|new|giv[194]	_	_
26-33	3843-3852	variation	abstract[191]|abstract[194]	giv[191]|giv[194]	_	_
26-34	3853-3855	in	abstract[191]|abstract[194]	giv[191]|giv[194]	_	_
26-35	3856-3860	TNBC	abstract[191]|abstract[194]|abstract	giv[191]|giv[194]|giv	coref	27-26
26-36	3861-3862	.	_	_	_	_

#Text=This limited progress must be balanced against the recognition that genomic and epigenomic alterations have long been considered as two separate molecular mechanisms participating in TNBC pathogenesis .
27-1	3863-3867	This	abstract[196]	new[196]	_	_
27-2	3868-3875	limited	abstract[196]	new[196]	_	_
27-3	3876-3884	progress	abstract[196]	new[196]	_	_
27-4	3885-3889	must	_	_	_	_
27-5	3890-3892	be	_	_	_	_
27-6	3893-3901	balanced	_	_	_	_
27-7	3902-3909	against	_	_	_	_
27-8	3910-3913	the	abstract[197]	new[197]	_	_
27-9	3914-3925	recognition	abstract[197]	new[197]	_	_
27-10	3926-3930	that	_	_	_	_
27-11	3931-3938	genomic	abstract[198]	new[198]	_	_
27-12	3939-3942	and	abstract[198]	new[198]	_	_
27-13	3943-3953	epigenomic	abstract[198]	new[198]	_	_
27-14	3954-3965	alterations	abstract[198]	new[198]	_	_
27-15	3966-3970	have	_	_	_	_
27-16	3971-3975	long	_	_	_	_
27-17	3976-3980	been	_	_	_	_
27-18	3981-3991	considered	_	_	_	_
27-19	3992-3994	as	_	_	_	_
27-20	3995-3998	two	_	_	_	_
27-21	3999-4007	separate	_	_	_	_
27-22	4008-4017	molecular	_	_	_	_
27-23	4018-4028	mechanisms	_	_	_	_
27-24	4029-4042	participating	_	_	_	_
27-25	4043-4045	in	_	_	_	_
27-26	4046-4050	TNBC	organization|abstract[200]	giv|giv[200]	coref|coref	28-32|28-32
27-27	4051-4063	pathogenesis	abstract[200]	giv[200]	_	_
27-28	4064-4065	.	_	_	_	_

#Text=The objective of this investigation is to deconvolute the genomic and epigenomic interaction landscape , and to discover and characterize the molecular networks and signaling pathways perturbed by these interactions in TNBC .
28-1	4066-4069	The	abstract[201]	new[201]	_	_
28-2	4070-4079	objective	abstract[201]	new[201]	_	_
28-3	4080-4082	of	abstract[201]	new[201]	_	_
28-4	4083-4087	this	abstract[201]|abstract[202]	new[201]|new[202]	_	_
28-5	4088-4101	investigation	abstract[201]|abstract[202]	new[201]|new[202]	_	_
28-6	4102-4104	is	_	_	_	_
28-7	4105-4107	to	_	_	_	_
28-8	4108-4119	deconvolute	_	_	_	_
28-9	4120-4123	the	abstract[204]	new[204]	_	_
28-10	4124-4131	genomic	abstract[204]	new[204]	_	_
28-11	4132-4135	and	abstract[204]	new[204]	_	_
28-12	4136-4146	epigenomic	abstract[204]	new[204]	_	_
28-13	4147-4158	interaction	abstract|abstract[204]	new|new[204]	_	_
28-14	4159-4168	landscape	abstract[204]	new[204]	_	_
28-15	4169-4170	,	_	_	_	_
28-16	4171-4174	and	_	_	_	_
28-17	4175-4177	to	_	_	_	_
28-18	4178-4186	discover	_	_	_	_
28-19	4187-4190	and	_	_	_	_
28-20	4191-4203	characterize	_	_	_	_
28-21	4204-4207	the	abstract[205]|abstract[206]	new[205]|new[206]	coref|coref|coref|coref	30-15[221_205]|30-15[222_206]|30-15[221_205]|30-15[222_206]
28-22	4208-4217	molecular	abstract[205]|abstract[206]	new[205]|new[206]	_	_
28-23	4218-4226	networks	abstract[205]|abstract[206]	new[205]|new[206]	_	_
28-24	4227-4230	and	abstract[206]	new[206]	_	_
28-25	4231-4240	signaling	abstract[206]|abstract[207]	new[206]|new[207]	coref	30-19[223_207]
28-26	4241-4249	pathways	abstract[206]|abstract[207]	new[206]|new[207]	_	_
28-27	4250-4259	perturbed	_	_	_	_
28-28	4260-4262	by	_	_	_	_
28-29	4263-4268	these	abstract[208]	giv[208]	_	_
28-30	4269-4281	interactions	abstract[208]	giv[208]	_	_
28-31	4282-4284	in	abstract[208]	giv[208]	_	_
28-32	4285-4289	TNBC	abstract[208]|event	giv[208]|giv	coref	29-6
28-33	4290-4291	.	_	_	_	_

#Text=Our working hypothesis was that TNBC originates from a complex interplay between genomic ( both germline and somatic ) variation and epigenomic variations .
29-1	4292-4295	Our	person|abstract[211]	giv|new[211]	ana|ana	30-1|30-1
29-2	4296-4303	working	abstract[211]	new[211]	_	_
29-3	4304-4314	hypothesis	abstract[211]	new[211]	_	_
29-4	4315-4318	was	_	_	_	_
29-5	4319-4323	that	_	_	_	_
29-6	4324-4328	TNBC	abstract	giv	coref	30-27
29-7	4329-4339	originates	_	_	_	_
29-8	4340-4344	from	_	_	_	_
29-9	4345-4346	a	abstract[213]	giv[213]	_	_
29-10	4347-4354	complex	abstract[213]	giv[213]	_	_
29-11	4355-4364	interplay	abstract[213]	giv[213]	_	_
29-12	4365-4372	between	abstract[213]	giv[213]	_	_
29-13	4373-4380	genomic	abstract[213]|abstract	giv[213]|new	appos	29-15[215_0]
29-14	4381-4382	(	_	_	_	_
29-15	4383-4387	both	abstract[215]	giv[215]	coref	31-9[0_215]
29-16	4388-4396	germline	abstract[215]	giv[215]	_	_
29-17	4397-4400	and	_	_	_	_
29-18	4401-4408	somatic	_	_	_	_
29-19	4409-4410	)	_	_	_	_
29-20	4411-4420	variation	abstract	giv	coref	31-9[229_0]
29-21	4421-4424	and	_	_	_	_
29-22	4425-4435	epigenomic	abstract[217]	new[217]	_	_
29-23	4436-4446	variations	abstract[217]	new[217]	_	_
29-24	4447-4448	.	_	_	_	_

#Text=We further hypothesized that these complex arrays of interacting genomic and epigenomic factors affect entire molecular networks and signaling pathways which , in turn , drive TNBC .
30-1	4449-4451	We	person	giv	ana	31-1
30-2	4452-4459	further	_	_	_	_
30-3	4460-4472	hypothesized	_	_	_	_
30-4	4473-4477	that	_	_	_	_
30-5	4478-4483	these	abstract[219]	new[219]	_	_
30-6	4484-4491	complex	abstract[219]	new[219]	_	_
30-7	4492-4498	arrays	abstract[219]	new[219]	_	_
30-8	4499-4501	of	_	_	_	_
30-9	4502-4513	interacting	_	_	_	_
30-10	4514-4521	genomic	abstract[220]	new[220]	_	_
30-11	4522-4525	and	abstract[220]	new[220]	_	_
30-12	4526-4536	epigenomic	abstract[220]	new[220]	_	_
30-13	4537-4544	factors	abstract[220]	new[220]	_	_
30-14	4545-4551	affect	_	_	_	_
30-15	4552-4558	entire	abstract[221]|abstract[222]	giv[221]|giv[222]	_	_
30-16	4559-4568	molecular	abstract[221]|abstract[222]	giv[221]|giv[222]	_	_
30-17	4569-4577	networks	abstract[221]|abstract[222]	giv[221]|giv[222]	_	_
30-18	4578-4581	and	abstract[222]	giv[222]	_	_
30-19	4582-4591	signaling	abstract[222]|abstract[223]	giv[222]|giv[223]	_	_
30-20	4592-4600	pathways	abstract[222]|abstract[223]	giv[222]|giv[223]	_	_
30-21	4601-4606	which	_	_	_	_
30-22	4607-4608	,	_	_	_	_
30-23	4609-4611	in	_	_	_	_
30-24	4612-4616	turn	_	_	_	_
30-25	4617-4618	,	_	_	_	_
30-26	4619-4624	drive	_	_	_	_
30-27	4625-4629	TNBC	abstract	giv	_	_
30-28	4630-4631	.	_	_	_	_

#Text=We addressed these hypotheses by integrating information on germline variation from GWAS with information on somatic and epigenomic variation from TCGA using gene expression as the intermediated phenotype .
31-1	4632-4634	We	person	giv	_	_
31-2	4635-4644	addressed	_	_	_	_
31-3	4645-4650	these	abstract[226]	new[226]	_	_
31-4	4651-4661	hypotheses	abstract[226]	new[226]	_	_
31-5	4662-4664	by	_	_	_	_
31-6	4665-4676	integrating	_	_	_	_
31-7	4677-4688	information	abstract[227]	giv[227]	coref	31-14[231_227]
31-8	4689-4691	on	abstract[227]	giv[227]	_	_
31-9	4692-4700	germline	abstract[227]|abstract|abstract[229]	giv[227]|giv|giv[229]	coref|coref	31-16[232_229]|31-16[232_229]
31-10	4701-4710	variation	abstract[227]|abstract[229]	giv[227]|giv[229]	_	_
31-11	4711-4715	from	abstract[227]|abstract[229]	giv[227]|giv[229]	_	_
31-12	4716-4720	GWAS	abstract[227]|abstract[229]|abstract	giv[227]|giv[229]|giv	_	_
31-13	4721-4725	with	_	_	_	_
31-14	4726-4737	information	abstract[231]	giv[231]	_	_
31-15	4738-4740	on	abstract[231]	giv[231]	_	_
31-16	4741-4748	somatic	abstract[231]|abstract[232]	giv[231]|giv[232]	_	_
31-17	4749-4752	and	abstract[231]|abstract[232]	giv[231]|giv[232]	_	_
31-18	4753-4763	epigenomic	abstract[231]|abstract[232]	giv[231]|giv[232]	_	_
31-19	4764-4773	variation	abstract[231]|abstract[232]	giv[231]|giv[232]	_	_
31-20	4774-4778	from	abstract[231]|abstract[232]	giv[231]|giv[232]	_	_
31-21	4779-4783	TCGA	abstract[231]|abstract[232]|abstract	giv[231]|giv[232]|giv	_	_
31-22	4784-4789	using	_	_	_	_
31-23	4790-4794	gene	abstract|abstract[235]	giv|giv[235]	_	_
31-24	4795-4805	expression	abstract[235]	giv[235]	_	_
31-25	4806-4808	as	_	_	_	_
31-26	4809-4812	the	_	_	_	_
31-27	4813-4826	intermediated	_	_	_	_
31-28	4827-4836	phenotype	_	_	_	_
31-29	4837-4838	.	_	_	_	_
